Torsten Hombeck, Ph.D.
Senior Vice President, Chief Financial Officer & Spokesperson of the Management Board

Rajesh Malik, M.D.
Senior Vice President, Chief Medical Officer & Member of the Management Board

Christine Boisclair
Senior Vice President, Global Regulatory Affairs

Colin Freund
Senior Vice President & Chief Business Officer

Greg Hamm
Senior Vice President, Human Resources & Corporate Integration

Brent Hatzis-Schoch
Senior Vice President & General Counsel

Jill Porter, Ph.D.
Senior Vice President, Pharmaceutical Development

Torsten Hombeck, Ph.D.
Senior Vice President, Chief Financial Officer & Spokesperson of the Management Board

Dr. Torsten Hombeck is the Chief Financial Officer and spokesperson of the Management Board of Agennix AG. Prior to serving as Chief Financial Officer of Agennix AG, he held positions of increasing responsibility in finance at GPC Biotech AG, which he joined in 1999, including the position of Chief Financial Officer starting in December 2007.

Dr. Hombeck previously held positions in corporate finance and controlling at Beiersdorf AG, an international branded consumer products company. Dr. Hombeck holds a Masters’s degree in business administration from the European Business School in Oestrich-Winkel, Germany, where he also received his Ph.D. in Finance.

Rajesh Malik, M.D.
Senior Vice President, Chief Medical Officer & Member of the Management Board

Dr. Rajesh Malik is Chief Medical Officer of Agennix AG. He joined Agennix Inc. as Chief Medical Officer in January 2007. Dr. Malik has more than 25 years of combined clinical and industry oncology experience. Before joining Agennix, he was Chief Medical Officer at Adherex Technologies, where he directed global clinical and regulatory development strategy for three oncology product candidates. He was also previously Executive Director at EMD Pharmaceuticals, the U.S. affiliate of Merck KGaA, where he directed the global clinical development strategy for several oncology product candidates. Dr. Malik also served as Associate Director at Bristol-Myers Squibb, where he was responsible for the global clinical development strategy for an oral taxane and for the company’s pediatric oncology initiatives. Dr. Malik received his M.D. from the University of Sheffield Medical School in the United Kingdom. He served his residency at Duke University Medical Center and hematology-oncology fellowships at Children’s Hospital of Philadelphia and Duke University Medical Center.

Christine Boisclair
Senior Vice President, Global Regulatory Affairs

Christine Boisclair is Senior Vice President, Global Regulatory Affairs of Agennix AG. Ms. Boisclair has over twenty years of U.S. and European regulatory affairs experience, covering both drugs and biologics in a variety of therapeutic areas, including oncology and anti-infectives.

She joined Agennix AG in July 2011 from OSI Pharmaceuticals, Inc., where she worked for over ten years in positions of increasing responsibility, most recently serving as Vice President, Regulatory Affairs.

At OSI, she built up the regulatory affairs department and served as the regulatory lead for the successful New Drug Application (NDA) for Tarceva® (erlotinib) in NSCLC, as well as the subsequent supplemental NDAs for pancreatic cancer and NSCLC maintenance. Prior to OSI, she worked at several biotechnology and pharmaceutical companies, including Genzyme, Searle, and Glaxo. She holds a Bachelor of Science Honors Degree in Biochemistry from York University in the United Kingdom.

Colin Freund
Senior Vice President & Chief Business Officer

Colin Freund is Chief Business Officer. Prior to his position at Agennix AG, he was Senior Vice President, Business Development at GPC Biotech AG, which he joined in 2002. Previously he held the position of Vice President, Business Development at Double Twist, Inc., Oakland, CA, where he was responsible for creating alliances with a variety of genomics and proteomics companies. Prior to joining Double Twist.

Mr. Freund was a project manager at Boston Consulting Group, San Francisco, CA, and London, UK, where he managed assignments in the healthcare and high technology practice areas. Mr. Freund received his Bachelor of Arts degree in Economics and Management Studies from the University of Cambridge, United Kingdom, and his Master’s degree in Business Administration from Stanford University (U.S.).

Greg Hamm
Senior Vice President, Human Resources & Corporate Integration

Gregory Hamm is Senior Vice President, Human Resources & Corporate Integration of Agennix AG. Prior to his position at Agennix, he held positions of increasing responsibility at GPC Biotech AG, which he joined in 1999 as Vice President, Bioinformatics and Information Technology, as well as Site Head of the Princeton facility. In 2001, Mr. Hamm was also appointed Vice President, Corporate Integration, which included responsibility for Human Resources worldwide. In 2007, Mr. Hamm assumed the role of Senior Vice President, Human Resources & Corporate Integration.

Mr. Hamm was previously Vice President, Bioinformatics, at Genome Therapeutics Corporation. Before 1995, Mr. Hamm was Director of the Molecular Biology Computing Laboratory at Rutgers University (U.S.). Earlier he was the founder of the EMBL Data Library and Head of Computing at the European Molecular Biology Laboratory (EMBL) in Heidelberg (Germany).

Brent Hatzis-Schoch
Senior Vice President & General Counsel

Brent Hatzis-Schoch is Senior Vice President & General Counsel of Agennix AG. Prior to his position at Agennix, he served GPC Biotech AG as General Counsel, which he joined in 2003. Earlier in his career, Mr. Hatzis-Schoch was Associate General Counsel for Global Research & Development at Pharmacia Corporation, where he also held various other senior legal positions in the transactional and international areas.

Previously, he was European legal counsel to Baxter Healthcare, based in Brussels, Belgium. He began his career in private practice in the United States and Germany. Mr. Hatzis-Schoch received his law degree from George Washington University, Washington D.C. (U.S.).

Jill Porter, Ph.D.
Senior Vice President, Pharmaceutical Development

Dr. Jill Porter is Senior Vice President, Pharmaceutical Development of Agennix AG. Dr. Porter has nearly twenty years of biopharmaceutical industry experience. Prior to joining Agennix AG in June 2011, she held senior executive positions with responsibility for manufacturing and process development at Taligen Therapeutics, Altus Pharmaceuticals, and Alexion Pharmaceuticals.

She worked for many years in positions of increasing responsibility at Hoffman-La Roche, including leading the Biopharmaceuticals department, with responsibility for the clinical and commercial manufacturing of two biologic drugs. Dr. Porter has experience in clinical and commercial supply chain management, as well as with regulatory filings and product approvals. She received a Ph.D. in agricultural engineering from Purdue University (U.S.) and a Masters’s degree in business administration from Columbia University (U.S.).